295 related articles for article (PubMed ID: 23150264)
1. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
Dhamija N; Rawat P; Mitra D
Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
4. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
5. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
Kulkosky J; Pomerantz RJ
Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
[TBL] [Abstract][Full Text] [Related]
6. Hide-and-seek: the challenge of viral persistence in HIV-1 infection.
Geeraert L; Kraus G; Pomerantz RJ
Annu Rev Med; 2008; 59():487-501. PubMed ID: 17845138
[TBL] [Abstract][Full Text] [Related]
7. Latency: the hidden HIV-1 challenge.
Marcello A
Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
[TBL] [Abstract][Full Text] [Related]
8. [Molecular basis of HIV-1 latency - part I: physiology of HIV-1 latency].
Schwartz C; Le Douce V; Cherrier T; Redel L; Marban C; Aunis D; Rohr O
Med Sci (Paris); 2010 Feb; 26(2):159-63. PubMed ID: 20188047
[TBL] [Abstract][Full Text] [Related]
9. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
[TBL] [Abstract][Full Text] [Related]
11. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
12. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
13. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.
Colin L; Van Lint C
Retrovirology; 2009 Dec; 6():111. PubMed ID: 19961595
[TBL] [Abstract][Full Text] [Related]
14. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 latency and eradication of long-term viral reservoirs.
Coiras M; Lopez-Huertas MR; Alcami J
Discov Med; 2010 Mar; 9(46):185-91. PubMed ID: 20350483
[TBL] [Abstract][Full Text] [Related]
16. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
Hezareh M
Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
[TBL] [Abstract][Full Text] [Related]
17. [HIV eradication--facts and fiction].
Jaeger H; Wolf E
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
[No Abstract] [Full Text] [Related]
18. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
[TBL] [Abstract][Full Text] [Related]
19. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
20. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection.
Turriziani O; Andreoni M; Antonelli G
Clin Microbiol Infect; 2010 Oct; 16(10):1518-24. PubMed ID: 20673260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]